683 Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

683 Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-42,000	Closed	-$403K	–	176
2019 Q2	$403K	Hold	42,000	–	–	0.04%	118
2019 Q1	$1.13M	Buy	42,000 +2,471	+6%	+$62.9K	0.1%	91
2018 Q4	$893K	Buy	39,529 +3,774	+11%	+$148K	0.05%	110
2018 Q3	$1.97M	Buy	35,755 +5,755	+19%	+$367K	0.13%	82
2018 Q2	$2.14M	Hold	30,000	–	–	0.14%	80
2018 Q1	$1.84M	Buy	+30,000	New	+$2.63M	0.16%	83

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

683 Capital Management's TTPH Position: Q3 2019 in Review

683 Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 42,000 shares — an estimated $403K sold.

683 Capital Management first reported a position in TTPH in Q1 2018 and held it in 6 quarters. The position peaked at $2.14M in Q2 2018. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

683 Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
683 Capital Management sold 42,000 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $403K.
683 Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2018 and held it in 6 quarters.
683 Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $2.14M in Q2 2018.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on 683 Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.